Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.59 USD | -0.90% | -3.49% | -47.01% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Financials (USD)
Sales 2024 * | 967M | Sales 2025 * | 1.09B | Capitalization | 2.73B |
---|---|---|---|---|---|
Net income 2024 * | 110M | Net income 2025 * | 221M | EV / Sales 2024 * | 2.2 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 864M | EV / Sales 2025 * | 1.72 x |
P/E ratio 2024 * |
26.4
x | P/E ratio 2025 * |
12.7
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | -0.90% | ||
1 week | -3.49% | ||
Current month | -10.28% | ||
1 month | -7.58% | ||
3 months | -38.98% | ||
6 months | -27.81% | ||
Current year | -47.01% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | 0.00% | - | |
1.24% | 16 M€ | -7.62% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 16.59 | -0.90% | 1,296,887 |
24-04-23 | 16.74 | -1.47% | 1,476,024 |
24-04-22 | 16.99 | +1.01% | 1,156,988 |
24-04-19 | 16.82 | -1.46% | 3,628,011 |
24-04-18 | 17.07 | -0.70% | 988,365 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.01% | 2.73B | |
+4.09% | 43.84B | |
+46.85% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ACAD Stock